FREE DAILY AND WEEKLY NEWSLETTERS OFFERED BY CONTENT OF INTEREST
Did you find this article relevant? Subscribe to UroToday-GUOncToday!
The fields of GU Oncology and Urology are advancing rapidly including new treatments, enrolling clinical trials, screening and surveillance recommendations along with updated guidelines. Join us as one of our subscribers who rely on UroToday as their must-read source for the latest news and data on drugs. Sign up today for blogs, video conversations, conference highlights and abstracts from peer-review publications by disease and condition delivered to your inbox and read on the go.
As a result, the field has been implementing many interventional trials in the “active surveillance” setting. These trials may be ideal for patients with slightly higher risk of the low risk subsets, where adverse long-term outcomes from disease progression of prostate cancer may occur at a higher rate. Enrollment into a clinical trial for patients with favorable risk disease may also be welcome by patients who psychologically will not tolerate the idea of no active intervention. These types of trials may also be ideal for patients who desire low toxicity systemic intervention without the local side effects of either surgery or radiation. Finally, this setting may be ideal for the biologic study of novel agents or nutraceuticals, since the downside risk of a non-efficacious intervention is low, while important tissue and biomarker data can be acquired and analyzed.
The goal of these trials may not need to include the same primary endpoints as trials for patients with more advanced prostate cancer disease states. For example, regulatory agencies are unlikely to require overall survival benefit for patients undergoing intervention in the active surveillance setting. Prevention of patient progression to a potentially morbid and costly local therapy intervention may suffice for patients initially planning on active surveillance of prostate cancer.
Below I highlight select ongoing trials with interventions spanning a broad range, including exercise, dietary supplementation, low-risk medications, immunologic and even regulatory approved agents for more advanced prostate cancer with proven efficacy but acceptable toxicity profiles.
- Exercise (ERASE) – NCT03203460
- Exercise (ASX) – NCT02435472
- Low-fat diet and Fish Oil – NCT02176902
- Cholecalciferol supplement – NCT00887432
- Vitamin D and Omega-3 Fatty Acid – NCT03290417
- Aspirin and/or Vitamin D3 (PROVENT) – NCT03103152
- Metformin (MAST) – NCT01864096
- ProstAtak® Immunotherapy (ULYSSES) – NCT02768363
- Enzalutamide (ENACT) - NCT02799745
- Active Surveillance With or Without a 6 Months Apalutamide Treatment in Low Risk Prostate Cancer: A Phase II Randomized Multicenter Trial NCT03088124
- A Phase 2 Study of Apalutamide in Active Surveillance Patients - NCT02721979
Written by: Evan Yu, MD
- Tosoian JJ, Trock BJ, Landis P, et al. J Clin Oncol 2011; 29:2185-90.
- Klotz L, Vesprini D, Sethukavalan P, et al. J Clin Oncol 2015; 33:272-7.
- Musunuru HB, Klotz L, Vesprini D, et al. J Urol 2016; 196:1651-8.
Watch: Active Surveillance: Who is the Right Patient? - Matt Cooperberg